ORIGINAL RESEARCH MASTER STUDY

Biophysical Reaction-Diffusion Transport and Evolutionary Sanctuary Dynamics in Compact EGFR-Mutant Lung Adenocarcinoma

Luca Celebrano, M.D. Candidate

Department of Clinical Medicine and Surgery, University of Naples Federico II
Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy

bioRxiv ID: BIORXIV/2026/761610 Zenodo DOI: 10.5281/zenodo.23623653 License: CC-BY 4.0 Cohort: MSKCC N=604

1. The Adjuvant ADAURA Paradox

Late clinical relapse after osimertinib cessation without canonical resistance mutations

The Unsolved Clinical Dilemma

  • Osimertinib standard of care: 3-year adjuvant osimertinib shows dramatic DFS benefit in resected stage IB–IIIA EGFR-mutant NSCLC (ADAURA trial).
  • Post-cessation relapse wave: Upon 3-year drug cessation, disease-free survival drops significantly between months 36 and 60.
  • MRD Dynamics (Nature Medicine 2025): Longitudinal ctDNA monitoring demonstrates that up to 68% (19/28) of DFS or molecular residual disease events occur after drug discontinuation.
  • Absence of secondary mutations: Relapses post-discontinuation rarely exhibit secondary EGFR C797S or MET amplification, retaining sensitivity to osimertinib rechallenge.

Why Bulk Pharmacology Fails

  • Macroscopic vs Microscopic: Osimertinib has a vast systemic distribution volume (Vd ≈ 918 L) and high steady-state exposure.
  • Bulk tissue homogenates: Standard assays measure average tissue concentration, masking steep microscopic gradients.
  • The Missing Link: How can drug-sensitive founder clones survive 3 full years of daily targeted therapy without genetic resistance?
  • Hypothesis: Spatial architectural compaction creates microscopic pharmacological sanctuaries that harbor non-mutational drug-tolerant persisters (DTPs).

2. Transport Biophysics & Interstitial Fluid Dynamics

Elevated interstitial fluid pressure (Pi) collapses transvascular convection

Fluid Mechanics in Solid Tumor Architecture

  • Vascular Hyperpermeability & Impaired Lymphatics: Compact neoplastic nests develop uniform high interstitial fluid pressure (Pi ≈ 15–20 mmHg).
  • Collapse of Hydrostatic Gradient: As Pi approaches microvascular hydrostatic pressure (Pv), the convective transvascular driving force ΔP collapses to zero:
    Jv = Lp S [(Pv - Pi) - σ(πv - πi)] → 0
  • Strict Passive Fickian Diffusion: Convective interstitial fluid velocity vanishes (v ≈ 0). Small and large molecules must cross tissue solely by interstitial diffusion.
  • Diffusion-Consumption Balance: Metabolic uptake and cellular binding compete against diffusion, creating steep concentration gradients.

Two Anatomical Configurations

  • Cylindrical Perivascular Tumor Cord (Krogh Model): Diffusion proceeds centrifugally from a central capillary wall (r0 = 10 μm) outward toward the necrotic boundary.
  • Avascular Solid / Micropapillary Nest: Neoplastic cell aggregates surrounded by peripheral stroma. Diffusion proceeds centripetally from outer stromal microvessels inward toward the core.
  • Topological Equivalence: In both geometries, cells located at radial distance r > 165.9 μm from the nearest capillary receive sub-therapeutic drug concentrations.

3. Exact Modified Bessel K0 Solutions & Sanctuary Shell

Osimertinib penetration boundary versus physiological oxygen viability

Governing Helmholtz Equation

  • Steady-state cylindrical reaction-diffusion:
    1/r · d/dr(r · dC/dr) - (k/D)C = 0
  • Exact closed-form solution:
    C(r) = C0 · K0(r/λ) / K0(r0/λ) where penetration length λ = √(D/k) = 627.7 μm.
  • Critical Threshold (rcrit = 165.9 μm): At IC50 (θ = 0.35 C0), osimertinib falls below therapeutic efficacy.
  • Oxygen Boundary (rox ≈ 200 μm): Neoplastic cells remain viable within Krogh oxygen diffusion limit.
  • Viable Sanctuary Shell: A continuous rim of viable, sub-therapeutically exposed tumor cells:
    Δr = 200.0 - 165.9 = 34.1 μm
  • Macromolecules (ADCs/Bispecifics): rcrit = 47.4 μm → leaving >76% of viable cord uninhibited!
Figure 1: Biophysical Reaction-Diffusion Transport

4. Evolutionary Replicator Dynamics in the Sanctuary

Frequency-dependent subclonal competition and polymorphic Nash attractor

The Non-Zero-Sum Evolutionary Game

  • Competing Subclones:
    • Sensitive Proliferating Clone (x): High baseline fitness, rapid cycling.
    • Drug-Tolerant Persisters (1 - x): Slow cycling, chromatin-modified survival phenotype.
  • Continuous Replicator Dynamic:
    dx/dt = x · [ (Ax)1 - xTAx ]
  • Hawk-Dove Payoff Matrix: Mutual invasibility condition satisfied:
    a12 > a22 and a21 > a11
  • Internal Asymptotically Stable Attractor:
    Convergence to polymorphic Nash equilibrium:
    x* = 0.6133
    Lyapunov stability verified: λeig = -1.7934 < 0

Biological Significance

  • Phenotypic Diversity Preserved: The sanctuary does not select purely for resistant clones; it preserves an active sensitive subpopulation.
  • Tolerant Cushion: Persister cells provide microenvironmental shielding and paracrine survival signals.
  • Poised for Regrowth: Upon treatment discontinuation, the brake is released, triggering rapid sensitive cell clonal expansion.

5. Calibrated ADAURA Post-Cessation Regrowth Simulation

Predicting molecular ctDNA detection vs macroscopic radiographic CT relapse

Calibrated Exploratory Model Dynamics

  • Simulation Setup: Microscopic residual nest of N0 = 2,000 cells at month 36 (post-adjuvant completion).
  • Doubling Times: Tdouble = 25 days (sensitive), 120 days (persisters).
  • Molecular ctDNA Positivity: Reached at threshold 106 cells at 10.7 months post-cessation.
  • Macroscopic Radiographic Relapse: Reached at threshold 109 cells (1 cm lesion) at 16.1 months.
  • Actionable Lead Time Window:
    Δt = 16.1 - 10.7 = 5.4 months
  • Concordance with ADAURA Trial (Nat Med 2025): Empirical prospective ctDNA surveillance demonstrated median lead time of 4.7 months (95% CI: 2.2–5.6).
Figure 2: Evolutionary Game and Regrowth Kinetics

6. Real-World Clinical Audit: MSKCC Cohort (N=604)

Empirical validation across 5 IASLC histological growth architectures

Recurrence Stratification by Subtype

  • Monotonic Recurrence Rate (r = 0.983):
    • Lepidic (uncompacted): 4.55% (4/88)
    • Acinar: 14.67% (54/368)
    • Micropapillary: 21.62% (8/37)
    • Papillary: 25.58% (11/43)
    • Solid (compact): 30.88% (21/68)
  • A Priori Extreme Contrast (N=193): Comparing high-sanctuary (Solid/Micro, N=105) vs Lepidic (N=88):
    • Univariable Log-Rank: χ² = 20.39, p = 6.33 × 10-6
    • Stage-Adjusted Cox: HR = 6.75 (95% CI: 2.28–19.97, p = 5.52 × 10-4)
  • Confirmed EGFR-Mutant Subcohort (N=182): High-sanctuary recurrence 22.2% vs Low-sanctuary 13.4% (Log-Rank χ² = 2.53, p = 0.112; extreme strata χ² = 5.31, p = 0.021).
Figure 3: MSKCC Clinical Validation

7. Rigorous Multivariable Modeling & Cohort Insights

Lepidic protection drives outcome in early-stage surgically resected disease

Transparent Cox Proportional Hazards Models

Model Formulation Sample Size Adjusted HR (95% CI) p-value Key Biological Takeaway
Extreme Contrast (Solid/Micro vs Lepidic) N=193 (33 events) 6.75 (2.28 – 19.97) p = 5.52 × 10-4 Maximal biophysical transport contrast
Whole Cohort (Compact vs Non-Compact) N=604 (98 events) 1.32 (0.83 – 2.08) p = 0.238 Attenuated across predominant acinar intermediate
Whole Cohort (+ EGFR Mutational Status) N=604 (98 events) 1.30 (0.82 – 2.07) p = 0.258 Independent of EGFR genotype at baseline
5-Subtype Decomposition (Acinar Reference) N=604 (98 events) Lepidic HR = 0.25 (0.09–0.70)
Solid HR = 1.48 (0.89–2.49)		 p = 0.0084
p = 0.133		 Prognostic separation is driven by profound protective effect of lepidic growth
*Methodological Honesty: Median RFS follow-up is 21.4 months (77 patients at 36 mo, 3 at 60 mo). Solid median RFS is 40.2 months (supported by 3 patients at risk beyond 40 mo). The MSKCC cohort demonstrates baseline architectural prognosis in resected chemo/TKI-naive patients.

8. Translational Roadmap & Clinical Decision Matrix

Histology-guided post-cessation ctDNA surveillance and preemptive intervention

Actionable Clinical Architecture

  • Risk-Stratified Post-Cessation Surveillance:
    • Low-Sanctuary (Lepidic / Acinar): Low baseline risk (4.5%–14.7% recurrence). Standard clinical/radiographic monitoring every 6 months.
    • High-Sanctuary (Solid / Micropapillary ≥ 20%): High intrinsic recurrence risk and sanctuary shells. Intensive longitudinal ctDNA screening every 3 months from month 36 to 60.
  • Exploiting the 5.4-Month Window: ctDNA detects subclinical relapse at 10.7 months post-cessation, providing a 5.4-month therapeutic window before macroscopic CT relapse at 16.1 months.
  • Preemptive Rechallenge: Re-initiating osimertinib upon molecular ctDNA detection (before secondary genetic mutations emerge) intercepts clinical recurrence.
Figure 4: Translational ADAURA Decision Matrix

9. Rational Combination Synergy (ADCs & Bispecifics)

Targeted perivascular cytoreduction collapses interstitial fluid pressure and expands TKI penetration

The Complementary Transport Paradox

  • Small-Molecule Osimertinib: Deep interstitial penetration (rcrit = 165.9 μm), but leaves a viable outer sanctuary shell (Δr = 34.1 μm).
  • Macromolecules (ADCs / Amivantamab): High molecular weight (150 kDa) restricts penetration strictly to the perivascular cuff (r ≤ 47.4 μm), leaving >76% of viable cord uninhibited.
  • Single-agent limitation: Neither modality alone can clear the entire neoplastic cord.

Mechanistic Synergy & Vessel Decompression

  • Perivascular Cytoreduction: ADCs/amivantamab induce intense localized apoptosis in the perivascular mantle (r ≤ 47.4 μm).
  • Metabolic Sink Elimination: Ablating perivascular cells eliminates metabolic clearance (k → 0 across the inner cuff).
  • Vascular Decompression: Relieves tumor solid stress, lowers interstitial fluid pressure (Pi ↓), and restores microvascular perfusion.
  • Sanctuary Collapse: Effective TKI penetration length expands:
    λeff = √(D / keff) >> 628 μm pushing rcrit dynamically beyond 200 μm and completely eradicating the hypoxic sanctuary shell!
  • Clinical Concordance: Explains the superior PFS of the MARIPOSA regimen (amivantamab + lazertinib) and ADC combinations.

10. Summary & Conclusions

A unified multiscale paradigm bridging physics, evolution, and thoracic oncology

Core Takeaways of the Study

  • 1. Spatial Compaction Creates Sanctuaries: Reaction-diffusion physics proves that osimertinib penetration falls below IC50 at 165.9 μm, establishing a viable 34.1 μm pharmacological sanctuary within oxygenated tumor cords.
  • 2. Non-Mutational Persistence & Game Theory: The sanctuary niche acts as an evolutionary shelter stabilizing an internal polymorphic Nash attractor (x* = 0.6133), preserving drug-sensitive founder clones during therapy.
  • 3. Calibrated Post-ADAURA Kinetics: Calibrated regrowth simulations project molecular ctDNA relapse at 10.7 months and radiographic CT relapse at 16.1 months, quantitatively matching prospective trial data (lead time Δt = 5.4 months).
  • 4. Real-World Clinical Evidence (MSKCC N=604): Prognostic separation is validated across IASLC histological patterns (HR = 6.75 in extreme biophysical contrast; Lepidic protective HR = 0.25, p = 0.0084).
  • 5. Actionable Clinical Translation: Histology-guided ctDNA MRD surveillance provides a 5.4-month preemptive window for osimertinib rechallenge, while ADC combinations rationally collapse the sanctuary shell via perivascular decompression.

11. Open Science, Declarations & Resources

Complete reproducibility and permanent archival

Declarations & Ethics

  • Funding: No external grants or industry sponsorship.
  • Competing Interests: The author declares no competing financial or non-financial interests.
  • Ethics: Secondary analysis of de-identified public clinical data (MSKCC cBioPortal, Caso et al., 2020); no institutional review board approval required.
  • Preprint Submission:
    • Portal: bioRxiv (Cancer Biology)
    • Tracking ID: BIORXIV/2026/761610
    • License: CC-BY 4.0 International

Code & Data Repositories

Slide 1 / 12